3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Dysplasia
14
Uterine Cervical Neoplasms
4
Vulvar Neoplasms
2
Squamous Intraepithelial Lesions
2
Precancerous Conditions
2
Papillomavirus Infections
2
HIV Infections
2
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Vaginal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Surveys and Questionnaires
23
Radiotherapy
22
Letrozole
22
Doxorubicin
21
Megestrol Acetate
20
olaparib
19
lenvatinib
19
Taxes
17
Specimen Handling
17
Docetaxel
17
Nivolumab
16
Magnetic Resonance Spectroscopy
16
dostarlimab
15
Metformin
15
Blood Specimen Collection
14
Observation
13
Gemcitabine
13
Biopsy
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
temsirolimus
10
abemaciclib
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Imiquimod
×
Gynecologic
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled